Table 1

Participant demographic and clinical characteristics

Group; mean (SD)*
CharacteristicControl, n = 16First-episode depression, n = 14Remitted-recurrent depression, n = 18Treatment-resistant/chronic depression, n = 20
Sex, % female61.162.588.980
Age, yr43.4 (9.1)42.5 (8.7)47.3 (9)49.6 (7.6)
Years of education14.2 (3.1)13.8 (3.3)13.4 (3.1)13.2 (3.5)
Age at onset, yrNA41.8 (8.7)26.3 (9.4)27.9 (8.5)
Duration of illness, moNA6.8 (4.3)245.8 (125.9)280.3 (142.4)
No. of previous episodesNA1.0 (0)5.1 (4.7)6.0 (6.2)
HAM-D at scanning§**2.8 (1.4)12.6 (7.4)2.6 (1.5)20.9 (4.6)
Treatment, %
Treatment
 Antidepressant
  SSRI or SSNRINA10072.285.0
  TCA or MAOINA6.316.740.0
  OthersNA6.322.255.0
  CombinationNA12.527.880.0
  No antidepressantNA011.13.7
 StabilizerNA016.730.0
 AntipsychoticNA6.311.140.0
 BenzodiazepineNA50.033.050.0
  • Antipsychotic = mainly atypical antipsychotics associated with antidepressants; Combination = designs concomitant use of antidepressants with different mechanisms of action (e.g., SSRI with reboxetine); HAM-D = Hamilton Depression Rating Scale; (19) MAOI = monoamine oxidase inhibitors; NA = not applicable; Others = noradrenaline reuptake inhibitors, noradrenaline and dopamine reuptake inhibitors, tetracyclic antidepressants, mirtazapine, metilfenidate or trazodone; SD = standard deviation; SSNRI = selective serotonin and noradrenaline reuptake inhibitors; SSRI = selective serotonin reuptake inhibitors; Stabilizer = includes anticonvulsants and mostly lithium; TCA = tricyclic antidepressant.

  • * Unless otherwise indicated.

  • Significant differences between first-episode and remitted-recurrent depression.

  • Significant differences between first-episode and treatment-resistant/chronic depression.

  • § Significant differences between first-episode depression and control.

  • Significant differences between treatment-resistant/chronic and remitted-recurrent depression.

  • ** Significant differences between treatment-resistant/chronic depression and control.